MX2019003546A - Virus oncoliticos optimizados y usos de los mismos. - Google Patents
Virus oncoliticos optimizados y usos de los mismos.Info
- Publication number
- MX2019003546A MX2019003546A MX2019003546A MX2019003546A MX2019003546A MX 2019003546 A MX2019003546 A MX 2019003546A MX 2019003546 A MX2019003546 A MX 2019003546A MX 2019003546 A MX2019003546 A MX 2019003546A MX 2019003546 A MX2019003546 A MX 2019003546A
- Authority
- MX
- Mexico
- Prior art keywords
- oncolytic viruses
- disclosed
- methods
- tumor
- optimized
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32351—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400310P | 2016-09-27 | 2016-09-27 | |
| US201662426724P | 2016-11-28 | 2016-11-28 | |
| PCT/US2017/053659 WO2018064134A1 (en) | 2016-09-27 | 2017-09-27 | Optimized oncolytic viruses and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003546A true MX2019003546A (es) | 2019-09-19 |
Family
ID=60245169
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003546A MX2019003546A (es) | 2016-09-27 | 2017-09-27 | Virus oncoliticos optimizados y usos de los mismos. |
| MX2023011105A MX2023011105A (es) | 2016-09-27 | 2019-03-27 | Virus oncoliticos optimizados y usos de los mismos. |
| MX2024004156A MX2024004156A (es) | 2016-09-27 | 2019-03-27 | Virus oncoliticos optimizados y usos de los mismos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011105A MX2023011105A (es) | 2016-09-27 | 2019-03-27 | Virus oncoliticos optimizados y usos de los mismos. |
| MX2024004156A MX2024004156A (es) | 2016-09-27 | 2019-03-27 | Virus oncoliticos optimizados y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11253558B2 (OSRAM) |
| EP (3) | EP4019029A1 (OSRAM) |
| JP (3) | JP7138946B2 (OSRAM) |
| CN (2) | CN117085047A (OSRAM) |
| AU (1) | AU2017335673B2 (OSRAM) |
| BR (1) | BR112019005700A2 (OSRAM) |
| CA (1) | CA3037573A1 (OSRAM) |
| MX (3) | MX2019003546A (OSRAM) |
| WO (1) | WO2018064134A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117085047A (zh) * | 2016-09-27 | 2023-11-21 | 萨特治疗学有限公司 | 优化的溶瘤病毒及其用途 |
| CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| CN110387353B (zh) * | 2018-04-16 | 2023-07-18 | 厦门大学 | 一种用于治疗肿瘤的柯萨奇b组病毒 |
| US20200352993A1 (en) * | 2019-05-09 | 2020-11-12 | Sator Therapeutics LLC | Delivery of oncolytic viruses using dendritic cells |
| CN111494433A (zh) * | 2020-04-26 | 2020-08-07 | 吴建国 | 一种新型溶瘤病毒在制备治疗结直肠癌药物的用途 |
| CN116507721A (zh) * | 2020-08-14 | 2023-07-28 | 上海行深生物科技有限公司 | 构建溶瘤病毒的方法 |
| CN116144608A (zh) * | 2021-09-29 | 2023-05-23 | 上海行深生物科技有限公司 | 病毒培养方法 |
| EP4608971A1 (en) * | 2022-10-27 | 2025-09-03 | Technische Universität Berlin | Method for generation of tumor-adapted oncolytic viruses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| CN102124335B (zh) * | 2008-05-22 | 2014-07-30 | 第一药品株式会社 | 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| US9919047B2 (en) | 2011-01-04 | 2018-03-20 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| RU2519763C9 (ru) * | 2012-11-26 | 2015-04-27 | Ольга Вячеславовна Матвеева | Метод иммунотерапии онкологических заболеваний и фармацевтические композиции на основе онколитического вируса сендай |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| CN117085047A (zh) | 2016-09-27 | 2023-11-21 | 萨特治疗学有限公司 | 优化的溶瘤病毒及其用途 |
-
2017
- 2017-09-27 CN CN202310850191.XA patent/CN117085047A/zh active Pending
- 2017-09-27 JP JP2019538097A patent/JP7138946B2/ja active Active
- 2017-09-27 US US15/716,974 patent/US11253558B2/en active Active
- 2017-09-27 CA CA3037573A patent/CA3037573A1/en active Pending
- 2017-09-27 BR BR112019005700-5A patent/BR112019005700A2/pt unknown
- 2017-09-27 EP EP22151209.8A patent/EP4019029A1/en not_active Withdrawn
- 2017-09-27 MX MX2019003546A patent/MX2019003546A/es unknown
- 2017-09-27 CN CN201780072002.3A patent/CN109982708B/zh active Active
- 2017-09-27 WO PCT/US2017/053659 patent/WO2018064134A1/en not_active Ceased
- 2017-09-27 AU AU2017335673A patent/AU2017335673B2/en active Active
- 2017-09-27 EP EP17794108.5A patent/EP3518947B1/en active Active
- 2017-09-27 EP EP22151215.5A patent/EP4023233A3/en active Pending
-
2019
- 2019-03-27 MX MX2023011105A patent/MX2023011105A/es unknown
- 2019-03-27 MX MX2024004156A patent/MX2024004156A/es unknown
-
2021
- 2021-12-06 US US17/543,333 patent/US20220088098A1/en active Pending
- 2021-12-06 US US17/543,206 patent/US12357664B2/en active Active
-
2022
- 2022-08-31 JP JP2022137786A patent/JP7462345B2/ja active Active
-
2024
- 2024-03-18 JP JP2024042134A patent/JP2024069529A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109982708A (zh) | 2019-07-05 |
| MX2024004156A (es) | 2024-04-23 |
| EP4023233A2 (en) | 2022-07-06 |
| EP3518947C0 (en) | 2023-07-05 |
| AU2017335673A1 (en) | 2019-04-11 |
| CN117085047A (zh) | 2023-11-21 |
| JP2022164823A (ja) | 2022-10-27 |
| WO2018064134A1 (en) | 2018-04-05 |
| CA3037573A1 (en) | 2018-04-05 |
| EP4023233A3 (en) | 2022-09-21 |
| US12357664B2 (en) | 2025-07-15 |
| JP7462345B2 (ja) | 2024-04-05 |
| EP3518947B1 (en) | 2023-07-05 |
| US20180085411A1 (en) | 2018-03-29 |
| AU2017335673B2 (en) | 2024-11-14 |
| MX2023011105A (es) | 2023-10-02 |
| JP7138946B2 (ja) | 2022-09-20 |
| EP3518947A1 (en) | 2019-08-07 |
| CN109982708B (zh) | 2023-05-23 |
| EP4019029A1 (en) | 2022-06-29 |
| JP2019533015A (ja) | 2019-11-14 |
| JP2024069529A (ja) | 2024-05-21 |
| BR112019005700A2 (pt) | 2021-07-27 |
| US20220088097A1 (en) | 2022-03-24 |
| US20220088098A1 (en) | 2022-03-24 |
| US11253558B2 (en) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011105A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
| MX2019012462A (es) | Terapia combinada. | |
| CY1120288T1 (el) | Συζευγματα αντισωματος-φαρμακου που περιεχουν duocarmycin για χρηση στη θεραπεια του καρκινου της ουροδοχου κυστης | |
| BR112019010020A2 (pt) | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| WO2016070051A3 (en) | Combination therapy for treatment of disease | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX375442B (es) | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. | |
| EA201790913A1 (ru) | Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| MX2024014239A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
| HK1248588A1 (zh) | 用於癌症治疗中的天花疫苗 | |
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| MX2020001856A (es) | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. | |
| NZ712691A (en) | C. novyi for the treatment of solid tumors in humans | |
| NZ726365A (en) | Combinations for treating cancers | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2020001727A (es) | Terapia de combinacion. | |
| EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
| SG10201807554QA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |